Nanoscope Therapeutics Named Finalist for ‘Dallas Innovates and D CEO Magazine’ 2022 Innovation Award
Bedford, TX, December 22, 2021 – Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, has been named a finalist for the D CEO and Dallas Innovates third annual Innovation Awards, which recognize companies that contribute to making Dallas-Fort Worth an innovation hub.
“We are proud to be part of the Dallas-Fort Worth biotech community and we greatly appreciate that D CEO and Dallas Innovates recognize our team’s efforts to develop a new treatment – a first-of-its kind gene therapy – to restore vision in patients blinded by retinal diseases,” said Nanoscope Co-Founder and CEO Sulagna Battacharya.
The 2022 Innovation Awards honor companies as well as business executives, entrepreneurs, and other leaders. Nanoscope was named a finalist in the category of Innovation in Biotech. All finalists will be recognized in the January/February issue of D CEO magazine and online at DallasInnovates.com. Winners will be revealed at an exclusive awards event in January.
Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) gene therapy platform is being developed for restoration of vision in patients blinded by retinal degenerative diseases, such as retinitis pigmentosa (RP), regardless of genetic mutations.
The company’s lead product, MCO-010, is in a Phase 2b multicenter, randomized, double-masked, sham controlled clinical trial in the U.S. for treatment of RP (NCT04945772). Results are expected in Q4 2022. In a Phase 1/2a open label trial of MCO-010, all 11 RP patients experienced restoration of vision to a level sufficient to resume activities of daily living.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with retinitis pigmentosa, Stargardt disease, and other IRDs as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/
Opus Biotech Communications